Business
Alternate Health Announces Strategic CBD Positioning
Alternate Health Announces Strategic CBD Positioning.
About this update from Alternate Health Corp
[{"type":"text","content":"\n\n\n\nAlternate Health Announces Strategic CBD Positioning\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nAlternate Health Announces Strategic CBD Positioning\nCanada NewsWire\nTORONTO, May 16, 2019\n\n\n\nExclusive focus on CBD product sales and cannabinoid medicine\n TORONTO, May 16, 2019 /CNW/ - Alternate Health Corp., (\"Alternate Health\" or the \"Company\") (CSE:AHG) (OTCQB:AHGIF), an international leader in CBD extraction, product development and distribution, announced today that the Company is restructuring its assets towards the potential $22 billion American CBD industry, and is focusing exclusively on hemp-derived cannabinoid extraction, and manufacturing and distributing proprietary medical grade products.\n\n \n \n\n \n\"Alternate Health's foundational goal has always been to lead the cannabis industry in innovation and new product development, using the research garnered through our software to effectively and efficiently serve patients,\" says Howard Mann, CEO of Alternate Health. \"With our recently announced $20M transaction with Blaine Labs, an FDA-approved production facility, we are uniquely poised to capture market share in this emerging industry. Since joining Alternate Health in December 2018, I have evaluated the various courses of business, and I feel CBD opportunities represent the Company's most significant and attainable business model.\"\nThe Future of the Cannabis Industry\nAccording to reports by market research firm Brightside Data, reported in Inc. Magazine, the U.S. CBD industry is estimated to reach $22 billion by 2022. The industry is currently valued at $591 million, but industry analysts expect demand to grow as stricter government regulations and oversight boost consumer confidence in CBD products. A key development will be the upcoming launch of national standards in product manufacturing, moving towards FDA-regulation and cGMP standards. \nAlternate Health was founded on the assumption that a value-added approach is the best strategy to capture the medical cannabis industry. Fundamentally, cann...